A compound having formula I: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein: R 2a R 2b R 2c V(CH 2) t U- is: (a) wherein: b is selected from 0, 1, 2, and 3; and a is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; or (b) wherein: V is N; T is CH, CR z, or N; and b is 0, 1, 2, 3, or 4; J is selected from NH 2, OH, and SH; each X is independently selected from hydrogen, deuterium, methyl, CF 3, and halogen; each R x is independently selected from (CH 2) z NH 2, (CH 2) z NHR 3, (CH 2) z NR 3 R 3, OR 3, OCF 3, OCH 2 F, OCHF 2, (CH 2) z -aromatic ring, (CH 2) z -heterocyclic ring, hydroxyl, halogen, C 1 -C 8 alkyl, (C 1 -C 8 alkyl)CF 3, (C 1 -C 8 alkyl)OH, C R 3, (CH 2) z C NH 2, (CH 2) z C NHR 3, (CH 2) z C NR 3 R 3, (CH 2) z NHC R 4, and (CH 2) z NR 4 C R 4; or taken together two R x attached to the same carbon atom of a heterocyclic ring together form =O; or taken together two R x form a C 3 -C 8 cycloalkyl ring, C 4 -C 8 cycloalkenyl ring, or 3 to 8 membered, saturated or partially unsaturated, heterocyclic ring, further wherein said cycloalkyl ring, cycloalkenyl ring, and heterocyclic ring are unsubstituted or substituted with one or more R z; or taken together two R x form an aromatic ring or heteroaromatic ring, further wherein said aromatic ring and heteroaromatic ring are unsubstituted or substituted with one or more R z; each R z is independently selected from halogen, C 1 -C 4 alkyl, OH, OR 3, CF 3, OCF 3, OCH 2 F, OCHF 2, NH 2, NHR 3, NR 3 R 3, and C CH 3; each R 3 is independently selected from C 1 -C 8 alkyl and O(C 1 -C 8 alkyl); each R 4 is independently selected from C 1 -C 8 alkyl and CF 3; R 5 is selected from OR 6 wherein R 6 is C 2 -C 8 alkyl, C 2 -C 8 alkyl, C 2 -C 8 alkenyl, (CH 2) u -5-6 membered saturated, unsaturated, or partially unsaturated, heterocyclic ring, (CFt 2) v -C 4 -C 8 cycloalkyl ring, (C 1 -C 8 -alkyl) w -C 4 -C 8 cycloalkenyl ring, (CH 2) s -aromatic ring, and (CH 2) s -heteroaromatic ring, wherein said heterocyclic ring, cycloalkyl ring, cycloalkenyl ring, heteroaromatic ring, and aromatic ring are unsubstituted or substituted with one or more R y, and said alkenyl is substituted with one or more R T; each R y is independently selected from halogen, OR 6, NH 2, NHR 6, NR 6 R 6, OH, CF 3, aromatic ring, C R 6, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, and C 2 -C 8 alkynyl, wherein each R 6 is independently C 1 -C 8 alkyl; each R T is independently selected from hydrogen, halogen, Si(R 3) 3, phenyl, and C 1 -C 8 alkyl; u is selected from 0, 1, and 2; v is selected from 0, 1, and 2; w is selected from 0, 1, and 2; s is selected from 0, 1, and 2; and each z is independently selected from 0, 1, 2, and 3. R 2a R 2b R 2c V(CH 2) t U- is: (a) wherein: b is selected from 0, 1, 2, and 3; and a is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; or (b) wherein: V is N; T is CH, CR z, or N; and b is 0, 1, 2, 3, or 4; (a) wherein: b is selected from 0, 1, 2, and 3; and a is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; or (b) wherein: V is N; T is CH, CR z, or N; and b is 0, 1, 2, 3, or 4; V is N; T is CH, CR z, or N; and b is 0, 1, 2, 3, or 4; J is selected from NH 2, OH, and SH; each X is independently selected from hydrogen, deuterium, methyl, CF 3, and halogen; each R x is independently selected from (CH 2) z NH 2, (CH 2) z NHR 3, (CH 2) z NR 3 R 3, OR 3, OCF 3, OCH 2 F, OCHF 2, (CH 2) z -aromatic ring, (CH 2) z -heterocyclic ring, hydroxyl, halogen, C 1 -C 8 alkyl, (C 1 -C 8 alkyl)CF 3, (C 1 -C 8 alkyl)OH, C R 3, (CH 2) z C NH 2, (CH 2) z C NHR 3, (CH 2) z C NR 3 R 3, (CH 2) z NHC R 4, and (CH 2) z NR 4 C R 4; or taken together two R x attached to the same carbon atom of a heterocyclic ring together form =O; or taken together two R x form a C 3 -C 8 cycloalkyl ring, C 4 -C 8 cycloalkenyl ring, or 3 to 8 membered, saturated or partially unsaturated, heterocyclic ring, further wherein said cycloalkyl ring, cycloalkenyl ring, and heterocyclic ring are unsubstituted or substituted with one or more R z; or taken together two R x form an aromatic ring or heteroaromatic ring, further wherein said aromatic ring and heteroaromatic ring are unsubstituted or substituted with one or more R z; each R z is independently selected from halogen, C 1 -C 4 alkyl, OH, OR 3, CF 3, OCF 3, OCH 2 F, OCHF 2, NH 2, NHR 3, NR 3 R 3, and C CH 3; each R 3 is independently selected from C 1 -C 8 alkyl and O(C 1 -C 8 alkyl); each R 4 is independently selected from C 1 -C 8 alkyl and CF 3; R 5 is selected from OR 6 wherein R 6 is C 2 -C 8 alkyl, C 2 -C 8 alkyl, C 2 -C 8 alkenyl, (CH 2) u -5-6 membered saturated, unsaturated, or partially unsaturated, heterocyclic ring, (CFt 2) v -C 4 -C 8 cycloalkyl ring, (C 1 -C 8 -alkyl) w -C 4 -C 8 cycloalkenyl ring, (CH 2) s -aromatic ring, and (CH 2) s -heteroaromatic ring, wherein said heterocyclic ring, cycloalkyl ring, cycloalkenyl ring, heteroaromatic ring, and aromatic ring are unsubstituted or substituted with one or more R y, and said alkenyl is substituted with one or more R T; each R y is independently selected from halogen, OR 6, NH 2, NHR 6, NR 6 R 6, OH, CF 3, aromatic ring, C R 6, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, and C 2 -C 8 alkynyl, wherein each R 6 is independently C 1 -C 8 alkyl; each R T is independently selected from hydrogen, halogen, Si(R 3) 3, phenyl, and C 1 -C 8 alkyl; u is selected from 0, 1, and 2; v is selected from 0, 1, and 2; w is selected from 0, 1, and 2; s is selected from 0, 1, and 2; and each z is independently selected from 0, 1, 2, and 3.